Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Brolucizumab is a follow-up to Novartis’ blockbuster AMD therapy Lucentis (ranibizumab), which has been competing toe-to-toe in the AMD market with Eylea for several years. Novartis reported ...

The global Age-Related Macular Degeneration (AMD) Market is poised for significant expansion over the next decade, with its value expected to grow from US$ 11.31 billion in 2023 to US$ 19.72 billion ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

and Novartis hopes it will appeal to doctors as this means cost per patient is lower compared with Lucentis and Bayer/Regeneron’s rival, Eylea (aflibercept). But there are concerns that doctors ...

Emergen Research Logo The development of anti-VEGF therapies, which inhibit the growth of abnormal blood vessels in the retina, reduces the ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Historically, the most common treatment for wet macular degeneration involved anti-vascular endothelial growth factor injections, such as Avastin, Lucentis, and Eylea. These drugs work by blocking ...

Historically, the most common treatment for wet macular degeneration (wAMD) involved anti-vascular endothelial growth factor (VEGF) injections, such as Avastin, Lucentis, and Eylea. These drugs work ...